22 . 09 . 2017

Xeltis CTO on the future of heart valve therapy at PCR London Valves


Xeltis CTO on the future of heart valve therapy at PCR London Valves

Martijn Cox, Xeltis’ CTO, will share his vision on the future of cardiovascular treatment during the “Where will we be in 2025?” session at PCR London Valves conference. A Biomedical engineer, PhD and Xeltis Co-Founder, Martijn Cox will share his insights from Xeltis’ progressive developments and scientific knowledge. “I’ve seen firsthand how much progress can […]

Scroll inside box for more news
Positive progression of ETR clinical trials at WCPCCS
20 . 07 . 2017

Positive progression of ETR clinical trials at WCPCCS

Patients inspire the Xeltis Team
7 . 07 . 2017

Patients inspire the Xeltis Team

7 Vidi grants reward Xeltis’ long-standing academic research partner
16 . 06 . 2017

7 Vidi grants reward Xeltis’ long-standing academic research partner

Xeltis’ RestoreX technology to be presented at TVT 2017
14 . 06 . 2017

Xeltis’ RestoreX technology to be presented at TVT 2017

Excellent Preclinical Performance of Restorative Aortic Valve
10 . 06 . 2017

Excellent Preclinical Performance of Restorative Aortic Valve

Excellent preclinical data show RestoreX potential for restorative vascular treatment
6 . 06 . 2017

Excellent preclinical data show RestoreX potential for restorative vascular treatment

Xeltis’ restorative heart valve therapy featured at EuroPCR
17 . 05 . 2017

Xeltis’ restorative heart valve therapy featured at EuroPCR

EuroPCR to host first ETR dedicated plenary session
15 . 05 . 2017

EuroPCR to host first ETR dedicated plenary session

Xeltis CTO at Biomedica Summit
8 . 05 . 2017

Xeltis CTO at Biomedica Summit

Professor Lange joins Xeltis’ Medical Advisory Board
2 . 05 . 2017

Professor Lange joins Xeltis’ Medical Advisory Board

Xeltis wins Gold Edison Award in medical technology
21 . 04 . 2017

Xeltis wins Gold Edison Award in medical technology

Potential of new cardiovascular restoration strategies presented at SFB
5 . 04 . 2017

Potential of new cardiovascular restoration strategies presented at SFB

Xeltis data on cardiovascular restoration with electrospun polymers at SFB
4 . 04 . 2017

Xeltis data on cardiovascular restoration with electrospun polymers at SFB

Xeltis shortlisted for Company of the Year
15 . 03 . 2017

Xeltis shortlisted for Company of the Year

<em>Science TM on ETR</em>: “Biology and engineering integrated at staggering level”
7 . 03 . 2017

Science TM on ETR: “Biology and engineering integrated at staggering level”

Preclinical heart valve restoration study in Biomaterials
3 . 03 . 2017

Preclinical heart valve restoration study in Biomaterials

Positive two-year preclinical data on Xeltis’ PV at HVS meeting
2 . 03 . 2017

Positive two-year preclinical data on Xeltis’ PV at HVS meeting

Xeltis clinical data published in JTCVS
24 . 02 . 2017

Xeltis clinical data published in JTCVS

“Xeltis has the potential to redefine heart valve replacement therapy”
21 . 02 . 2017

“Xeltis has the potential to redefine heart valve replacement therapy”

Leading cardiologist to present Xeltis’ bioabsorbable valve at CRT 2017
19 . 02 . 2017

Leading cardiologist to present Xeltis’ bioabsorbable valve at CRT 2017

Xeltis CTO’s entrepreneurial perspective at Innovation for Healthcare
14 . 02 . 2017

Xeltis CTO’s entrepreneurial perspective at Innovation for Healthcare

Xeltis is a 2017 Edison Awards Finalist
9 . 02 . 2017

Xeltis is a 2017 Edison Awards Finalist

“How to build a successful med-tech company”
8 . 02 . 2017

“How to build a successful med-tech company”

FDA gives Xeltis go ahead to begin trials in the USA
31 . 01 . 2017

FDA gives Xeltis go ahead to begin trials in the USA

Season’s Greetings: A Word from the CEO
23 . 12 . 2016

Season’s Greetings: A Word from the CEO

Introducing the RestoreX brand
21 . 12 . 2016

Introducing the RestoreX brand

Xeltis completes patient enrollment in Xplore-I trial
19 . 12 . 2016

Xeltis completes patient enrollment in Xplore-I trial

Xeltis receives nomination for 2017 Edison Awards
14 . 12 . 2016

Xeltis receives nomination for 2017 Edison Awards

Xeltis expands Clinical Advisory Board’s expertise with significant EU and US appointments
22 . 11 . 2016

Xeltis expands Clinical Advisory Board’s expertise with significant EU and US appointments

Xeltis announces multidisciplinary Scientific Advisory Board of global leading experts
1 . 11 . 2016

Xeltis announces multidisciplinary Scientific Advisory Board of global leading experts

Xeltis to introduce aortic valve program at TCT 2016 New Technology Forum
28 . 10 . 2016

Xeltis to introduce aortic valve program at TCT 2016 New Technology Forum

Three patients successfully implanted with Xeltis’ bioabsorbable pulmonary valve in Asia
21 . 10 . 2016

Three patients successfully implanted with Xeltis’ bioabsorbable pulmonary valve in Asia

Xeltis two steps closer to redefining heart valve replacement: highlights from EACTS 2016
10 . 10 . 2016

Xeltis two steps closer to redefining heart valve replacement: highlights from EACTS 2016

Two-year clinical data show positive functionality of Xeltis’ bioabsorbable cardiovascular device
5 . 10 . 2016

Two-year clinical data show positive functionality of Xeltis’ bioabsorbable cardiovascular device

First Heart Valve Enabling Heart Restoration Successfully Implanted
2 . 10 . 2016

First Heart Valve Enabling Heart Restoration Successfully Implanted

Xeltis data set to make an impact at EACTS 2016
1 . 10 . 2016

Xeltis data set to make an impact at EACTS 2016

Excitement builds about Xeltis’ potential from MedTech Strategist front cover
30 . 09 . 2016

Excitement builds about Xeltis’ potential from MedTech Strategist front cover

Leading cardiovascular experts join Xeltis Clinical Advisory Board
19 . 09 . 2016

Leading cardiovascular experts join Xeltis Clinical Advisory Board

Xeltis technology enables cardiovascular regeneration in high blood pressure, preclinical data showed at ISACB
9 . 09 . 2016

Xeltis technology enables cardiovascular regeneration in high blood pressure, preclinical data showed at ISACB

Martijn Cox: Bringing Xeltis technology to life
7 . 09 . 2016

Martijn Cox: Bringing Xeltis technology to life

Xeltis awarded extended ISO certification
8 . 07 . 2016

Xeltis awarded extended ISO certification

Xeltis joins launch of Dutch Regenerative Medicine institute
7 . 07 . 2016

Xeltis joins launch of Dutch Regenerative Medicine institute

Xeltis Celebrates 10th Anniversary
1 . 07 . 2016

Xeltis Celebrates 10th Anniversary

Meet the Xeltis team at Eindhoven Expat Fair
10 . 06 . 2016

Meet the Xeltis team at Eindhoven Expat Fair

Xeltis in-vivo data demonstrating Endogenous Tissue Restoration presented at WBC
21 . 05 . 2016

Xeltis in-vivo data demonstrating Endogenous Tissue Restoration presented at WBC

Xeltis late-breaking data at AATS set stage for the development of first bioabsorbable heart valve
17 . 05 . 2016

Xeltis late-breaking data at AATS set stage for the development of first bioabsorbable heart valve

Xeltis pulmonary valve on track for 2016 clinical trials – stated CEO at PCR Innovators Day
16 . 05 . 2016

Xeltis pulmonary valve on track for 2016 clinical trials – stated CEO at PCR Innovators Day

Xeltis bioabsorbable cardiovascular technology clinical data are late breaker at AATS
12 . 05 . 2016

Xeltis bioabsorbable cardiovascular technology clinical data are late breaker at AATS

Renowned start-up advocate met with Xeltis co-founder
10 . 05 . 2016

Renowned start-up advocate met with Xeltis co-founder

Laurent Grandidier in the 2016 Medicine Maker Power List 100
29 . 04 . 2016

Laurent Grandidier in the 2016 Medicine Maker Power List 100

Xeltis selected to present at EuroPCR Innovators Day
15 . 04 . 2016

Xeltis selected to present at EuroPCR Innovators Day

Innovation in MedTech invites Xeltis CEO back to present
14 . 04 . 2016

Innovation in MedTech invites Xeltis CEO back to present

US FDA granted Humanitarian Use Device for Xeltis pulmonary valve
23 . 03 . 2016

US FDA granted Humanitarian Use Device for Xeltis pulmonary valve

Xeltis pulmonary conduit data presented at HVS
17 . 03 . 2016

Xeltis pulmonary conduit data presented at HVS

Xeltis to present to leading investors at European forum
15 . 03 . 2016

Xeltis to present to leading investors at European forum

Xeltis CEO to present at leading BioCapital event
3 . 03 . 2016

Xeltis CEO to present at leading BioCapital event

Heart Awareness Month
24 . 02 . 2016

Heart Awareness Month

Xeltis’ QMS received ISO certification
18 . 02 . 2016

Xeltis’ QMS received ISO certification

Supporting CHD Awareness Week 2016
11 . 02 . 2016

Supporting CHD Awareness Week 2016

Xeltis appoints new CFO
2 . 02 . 2016

Xeltis appoints new CFO

Dutch figurehead Professor Jan Raaijmakers visits Xeltis
29 . 01 . 2016

Dutch figurehead Professor Jan Raaijmakers visits Xeltis

Leading Research Program NRP 63 featuring Xeltis’ technology
28 . 01 . 2016

Leading Research Program NRP 63 featuring Xeltis’ technology

How Xeltis overcame medtech financial challenges
22 . 01 . 2016

How Xeltis overcame medtech financial challenges

Xeltis-led research published in Tissue Engineering Part A
6 . 01 . 2016

Xeltis-led research published in Tissue Engineering Part A

Xeltis extends series B financing to €30M, signing off transformational year
17 . 12 . 2015

Xeltis extends series B financing to €30M, signing off transformational year

Nobel Laureate Professor Lehn visiting Xeltis
9 . 12 . 2015

Nobel Laureate Professor Lehn visiting Xeltis

Xeltis CEO Laurent Grandidier receives Award for Best CEO in Medical Devices
5 . 12 . 2015

Xeltis CEO Laurent Grandidier receives Award for Best CEO in Medical Devices

Xeltis nominates Michel Darnaud as new Chairman
19 . 11 . 2015

Xeltis nominates Michel Darnaud as new Chairman

The positive economics of the Xeltis technology
17 . 11 . 2015

The positive economics of the Xeltis technology

Xeltis completed second feasibility clinical trial on novel bioabsorbable cardiovascular device technology
10 . 11 . 2015

Xeltis completed second feasibility clinical trial on novel bioabsorbable cardiovascular device technology

Eliane Schutte joins the Xeltis Executive Team as Chief Development Officer
5 . 11 . 2015

Eliane Schutte joins the Xeltis Executive Team as Chief Development Officer

First ever bioabsorbable heart conduit by Xeltis implanted two years ago
23 . 10 . 2015

First ever bioabsorbable heart conduit by Xeltis implanted two years ago

Xeltis-led research on supramolecular polymer bioabsorbtion in Acta Biomaterialia
23 . 10 . 2015

Xeltis-led research on supramolecular polymer bioabsorbtion in Acta Biomaterialia

A heart-racing day for Heartbeat Foundation
19 . 10 . 2015

A heart-racing day for Heartbeat Foundation

Xeltis one of 15 most promising private medtech companies globally
14 . 10 . 2015

Xeltis one of 15 most promising private medtech companies globally

Martijn Cox on Xeltis research in Brabants Dagblad
30 . 09 . 2015

Martijn Cox on Xeltis research in Brabants Dagblad

Xeltis at Les Journées de Moscou, L’Obs’s Moscow Forum
24 . 09 . 2015

Xeltis at Les Journées de Moscou, L’Obs’s Moscow Forum

Xeltis proudly presents short movie of its first charity event
13 . 08 . 2015

Xeltis proudly presents short movie of its first charity event

Omroep Brabant portrays Xeltis in a video reportage
4 . 08 . 2015

Omroep Brabant portrays Xeltis in a video reportage

Cooperation is essential: Xeltis appeared in renowned Netherlands Heart Journal June issue
9 . 07 . 2015

Cooperation is essential: Xeltis appeared in renowned Netherlands Heart Journal June issue

Xeltis completes first study of Endogenous Tissue Restoration technology
19 . 05 . 2015

Xeltis completes first study of Endogenous Tissue Restoration technology

Xeltis nominates Michel Darnaud for election to its Board of Directors
18 . 05 . 2015

Xeltis nominates Michel Darnaud for election to its Board of Directors

Xeltis presenting on PCR Innovators day
11 . 05 . 2015

Xeltis presenting on PCR Innovators day

Xeltis’ CEO Laurent Grandidier meets Willem-Alexander, King of the Netherlands
28 . 04 . 2015

Xeltis’ CEO Laurent Grandidier meets Willem-Alexander, King of the Netherlands

Financieele Dagblad portrays Xeltis and its Dutch-Swiss culture
9 . 03 . 2015

Financieele Dagblad portrays Xeltis and its Dutch-Swiss culture

Le Temps writes about revolutionary approaches in heart surgery
17 . 02 . 2015

Le Temps writes about revolutionary approaches in heart surgery

Successful Start-Ups in the Netherlands: Xeltis is mentioned in Link Magazine
17 . 02 . 2015

Successful Start-Ups in the Netherlands: Xeltis is mentioned in Link Magazine

Xeltis welcomes Boris Warnack as a new member of the Executive Team
1 . 02 . 2015

Xeltis welcomes Boris Warnack as a new member of the Executive Team

Four million Euro to develop new vascular graft for kidney dialysis
19 . 01 . 2015

Four million Euro to develop new vascular graft for kidney dialysis

Xeltis’ investment round in Biotech Finances
12 . 12 . 2014

Xeltis’ investment round in Biotech Finances

Eindhovens Dagblad writes about Xeltis’ Series B financing
11 . 12 . 2014

Eindhovens Dagblad writes about Xeltis’ Series B financing

Xeltis closes EURO 27 million / USD 34 million series B Financing
2 . 12 . 2014

Xeltis closes EURO 27 million / USD 34 million series B Financing

Xeltis featured by Dutch television program
7 . 11 . 2014

Xeltis featured by Dutch television program

Dutch Minister of Finance visits Xeltis
4 . 11 . 2014

Dutch Minister of Finance visits Xeltis

Professor Schoen on supramolecular chemistry in Cardiology Today
3 . 06 . 2014

Professor Schoen on supramolecular chemistry in Cardiology Today

Xeltis’ recent article in Cardiology Today:
19 . 05 . 2014

Xeltis’ recent article in Cardiology Today:

Xeltis on the frontpage of News Medical
26 . 03 . 2014

Xeltis on the frontpage of News Medical

MDD leads with Xeltis story
12 . 03 . 2014

MDD leads with Xeltis story

Xeltis Completes Enrolment in World’s First Study of Spontaneous Tissue Growth
22 . 02 . 2014

Xeltis Completes Enrolment in World’s First Study of Spontaneous Tissue Growth

Xeltis Appoints Nobel Prize Winner  Prof. Jean-Marie Lehn To Its Advisory Board
7 . 01 . 2014

Xeltis Appoints Nobel Prize Winner Prof. Jean-Marie Lehn To Its Advisory Board

6 . 01 . 2014

6 . 01 . 2014

New CFO joins Xeltis’ awesome team
21 . 11 . 2013

New CFO joins Xeltis’ awesome team

Innovation in a changing medtech landscape
5 . 11 . 2013

Innovation in a changing medtech landscape

Xeltis CEO speaks at Life Science Week
9 . 10 . 2013

Xeltis CEO speaks at Life Science Week

Eindhoven – The world’s most inventive city
19 . 08 . 2013

Eindhoven – The world’s most inventive city

Xeltis wins ‘Next Gem Award in Medtech’
2 . 04 . 2013

Xeltis wins ‘Next Gem Award in Medtech’

Xeltis Team wishes all seasons greetings
5 . 03 . 2013

Xeltis Team wishes all seasons greetings

Xeltis selected as Hot Pick of the Month and featured in Clinica
8 . 02 . 2013

Xeltis selected as Hot Pick of the Month and featured in Clinica

Xeltis Director of R&D chosen to represent “innovation”
7 . 02 . 2013

Xeltis Director of R&D chosen to represent “innovation”

Xeltis re-launches website
5 . 02 . 2013

Xeltis re-launches website

Xeltis CEO Laurent Grandidier presents at two prestigious conferences
5 . 02 . 2013

Xeltis CEO Laurent Grandidier presents at two prestigious conferences

Xeltis 25 European medtech startups
5 . 02 . 2013

Xeltis 25 European medtech startups

Latest Tweets

Scroll inside box for more tweets

Latest Tweets

LinkedIn Posts

Scroll inside box for more posts
  • Positive Xeltis data from two clinical trials on Endogenous Tissue Restoration (ETR) applications show encouraging progression for the RestoreX technology and begin to confirm the long-term potential of Xeltis’ restorative approach. www.xeltis.com/news
  • Xeltis recognized as one of the 10 most promising startups of Brainport Eindhoven at the fourth edition of Startups-to-Watch by @e52, the regional news channel for innovation. Eindhoven is internationally recognised as a fertile ground for start up companies. www.xeltis.com
  • We are delighted about the Silver #SIAAwards received for our homepage design. Congratulations to our excellent California-based partner @schipperdesign. Learn about #Xeltis restorative #heartvalve therapy from our award-winning homepage here: www.xeltis.com A medical device platform with the first-ever bioabsorbable heart valves and blood vessels, enabling the natural restoration of the body part they replace.
  • “When will I need my next surgery? is a persistent question” explained patients living with #heartvalve replacement who mesmerized the Xeltis team on the company’s Second Patient Interaction Day. “We embraced dialogue with patient associations like De Hart&Vaatgroep at a very early stage”, stated Martijn Cox, Xeltis Co-Founder and CTO. “Listening, one of our corporate values, is an extremely insightful and motivational experience.” www.xeltis.com/news
  • 'Valve, Heal Thyself: Pioneers Seek Tissue-Engineered Fix for Faulty, Failing Cardiac Parts’ reports TCT on Xeltis’ restorativative #heartvalve therapy based on ETR plenary, read the article here https://lnkd.in/g4WThZ2 and learn more about Xeltis: http://www.xeltis.com A medical device platform with the first-ever bioabsorbable heart valves and blood vessels, enabling the natural restoration of the body part they replace.
  • Congratulations to our partner Eindhoven University of Technology and particularly to Patricia Dankers on receiving notable Vidi grants as recognition for top-quality research; we’re proud to be associated with such an innovative academic research institution. www.xeltis.com/news
  • “The growing sets of RestoreX data indicate a promising future for restorative heart valve therapy, making our technology prospectively relevant for interventional cardiologist” commented Xeltis CTO and co-founder, Martijn Cox, ahead of this week’s presentation on Xeltis’ restorative approach in heart valve therapy at TVT 2017 www.xeltis.com/news
  • Leading cardiac surgeon Dr Gregory Fontana on excellent outcomes from Xeltis restorative aortic valve preclinical program at ISMICS: “Xeltis' restorative valves may help reduce complications and improve valve durability, which is essential for younger and lower risk patients”. www.xeltis.com/news
  • “Xeltis excellent preclinical data of a restorative carotid artery confirm the potential of RestoreX technology for small diameter vascular treatment,” stated Martijn Cox, Xeltis CTO and Co-Founder. Xeltis latest in vivo vascular data have been presented at ISVTE scientific conference in Columbus, Ohio (USA). www.xeltis.com/news
  • Watch video highlights on Xeltis’ ETR restorative approach in heart valve therapy from EuroPCR 2017: http://www.xeltis.com https://lnkd.in/dbHidt3 Catch the highlights on Xeltis' ETR restorative approach in heart valve therapy from EuroPCR 2017: Learn more about Xeltis: http://www.xeltis.com
  • Xeltis is proud to contribute to the ImaValve research project with TU/e, promoting further solutions in heart valve therapy https://lnkd.in/d4pv9bc Learn more about the latest progress of Xeltis' own RestoreX technology for heart valve restorative therapy on our website: https://lnkd.in/dmNGAyb Xeltis’ pioneering approach to heart valve therapy was the focus of today’s plenary session “Bioresorbable valve therapy: tomorrow’s world” at EuroPCR. Global thought leaders in interventional cardiology discussed the unique science, early data and...
  • Xeltis’ pioneering approach to heart valve therapy was the focus of today’s EuroPCR plenary session “Bioresorbable valve therapy: tomorrow's world”. Global thought leaders discussed the unique science, early data and potential benefits of Endogenous Tissue Restoration (ETR) at the well-attended session. https://lnkd.in/gS5Y9e4
  • Xeltis’ ETR restorative approach will be discussed tomorrow at EuroPCR plenary session looking at future of heart valve therapy: 8:30 in Room 351, floor 3 https://lnkd.in/dAuX7bB Xeltis is a clinical-stage company developing medical devices enabling cardiovascular restoration.
  • EuroPCR 2017 is the first leading cardiology meeting to host a plenary session dedicated to Endogenous Tissue Restoration (ETR). ‘Bioresorbable valve therapy: tomorrow's world’ will discuss the potential of ETR and has global thought leaders to participate in chairing, presenting and acting as panelist for this interactive session. The plenary session will run from 8:30 to 10:00 am in Room 351 on Level 3. https://lnkd.in/gS5Y9e4
  • EuroPCR next week includes plenary session: ‘Bioresorbable valve therapy: tomorrow's world’. Stay ahead of the conversation about how ETR is the future of restorative heart valve therapy. Session will be co-chaired by Harvard Medical School’s Prof Edelman and Radcliffe Cardiology’s Prof Latib https://lnkd.in/dFcUtb5 Reinventing the heart valve.
  • Less than a week until #EuroPCR. This year will be the first ever plenary session dedicated to bioresorbable heart valve therapy. Taking place at 08:30, 17th May in Room 351. To learn more about ETR enabling technology please contact us or visit: www.xeltis.com/technology
  • Are you attending Euro PCR? This year will be the first ever plenary session dedicated to restorative heart valve therapy, taking place at 08:30, 17th May in Room 351. If you’re interested in learning more about this technology please contact us or visit www.xeltis.com/technology 2016 96th American Association for Thoracic Surgery (AATS) annual meeting: Xeltis 1-year feasibility clinical trial data showed significant improvement in patients’ general conditions. View PDF 3rd Heart Valve Society (HVS) annual meeting: Xeltis...
  • Martijn Cox, Xeltis CTO, will present the RestoreX technology as part of the regenerative medicine session at Biomedica 2017. https://lnkd.in/gS5Y9e4
  • Professor Rüdiger Lange has joined Xeltis’ Medical Advisory Board. The Medical Director of the German Heart Centre Munich will enhance Xeltis’ understanding of clinical needs and capability to address them with specific experience in the reconstruction of heart valves. https://lnkd.in/gS5Y9e4
  • Xeltis won the Gold Edison Award in medical technology for its RestoreX technology platform at the 2017 Edison Awards Gala in New York City last night. www.xeltis.com/news